Guidelines for the use of antipsychotic drug studies in healthy volunteers

Journal of Psychopharmacology

Volumn 11, Issue 3, 1997, Pages 201-209

  King, David J ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PROCHLORPERAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE;

CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DYSPHORIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; INSURANCE; MEDICAL ETHICS; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; VOLUNTEER;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; GREAT BRITAIN; HUMANS; PATIENT SELECTION;

EID: 0030826269     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100302     Document Type: Conference Paper

References (51)

1. Anderson B G, Reker D, Cooper T B (1981) Prolonged adverse effect of haloperidol in normal subjects. N Engl J Med 305: 643-644
2. Anderson B G, Reker D, Cooper T (1996) Drug-induced dysphoria. Br J Psychiat 168: 520
3. Angst J, Bech P, Bobon D et al. (1991) Report on the Third Consensus Conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiatry 24: 149-152
4. Association of the British Pharmaceutical Industries (1996) Good clinical (research) practice. ABPI, London
5. Barnes T R E (1992) Clinical assessment of the extrapyramidal side effects of antipsychotic drugs. J Psychopharmac 6: 214-221
6. Baruch I, Hemsley D R, Gray J A (1988) Latent inhibition and 'psychotic proneness' in normal subjects. Personal Ind Diff 9: 777-783
7. Braff D L, Geyer M A (1990) Sensorimotor gating and schizophrenia: human and animal model studies. Archs Gen Psychiat 47: 181-188
8. Braude W M, Barnes T R E, Gore SM (1983) Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiat 143: 139-150
9. Cassens, G, Inglis A K, Appelbaum P S, Gutheil T G (1990) Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16: 477-499
10. Clark C R, Geffen G M, Geffen L B (1989) Catecholamines and the covert orientation of attention in humans. Neuropsychologia 27: 131-139
11. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archs Gen Psychiat 49: 538-544
12. Frith C D (1987) The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med 17: 631-648
13. Gray J A, Feldon J, Rawlins J N P, Hemsley D R, Smith A D (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14: 1-84
14. Green J F, King D J (1996) Cognitive function in schizophrenia: the effect of drug treatment. CNS Drugs 6: 382-398
15. International Conference on Harmonisation (1996) Note for guidance on good clinical practice. ICH Topic E6, (CPMP/ICH/135/95). The European Agency for the Evaluation of Medicinal Products, London
16. Isah A O, Rawlins M D, Bateman D N (1991) Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmac 32: 677-684
17. Joseph M H, Frith C D, Waddington J L (1979) Dopaminergic mechanisms and cognitive deficit in schizophrenia. Psychopharmacology 63: 273-280
18. 1-dopamine receptor. Psychopharmacology 113: 149-156
19. 1-dopamine receptor binding and occupancy in man. Psychopharmacology 121: 300-308
20. 1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology 119: 1-8
21. King D J (1990) The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiat 157: 799-811
22. King D J (1993) Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In Hindmarch I, Stonier P D (eds), Human psychopharmacology: measures and methods, Vol IV. Wiley, Chichester, pp. 195-209
23. King D J (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiat Scand 89 (Suppl. 380): 53-58
24. King D J, Burke M and Lucas R A (1995) Antipsychotic drug-induced dysphoria. Br J Psychiat 167: 480-482
25. Kornetsky C, Pettit M, Wynne R, Evarts E V A (1959) A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. J Med Sci 105: 190-198
26. Liljequist R, Linnoila M, Mattila M J, Saario I, Seppälä T (1975) Effect of two weeks' treatment with thioridazine, chlorpromazine, sulpiride, and bromazepam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia 44: 205-208
27. Lilequist R, Linnoila M, Mattila M J (1978) Effect of diazepam and chlorpromazine on memory functions in man. Eur J Clin Pharmac 13: 339-343
28. Lubow R E, Ingberg-Sachs Y, Zalstein-Orda N, Gewirtz J C (1992) Latent inhibition in low and high 'psychotic-prone' normal subjects. Personal Ind Diff 13: 563-572
29. McClelland G R, Cooper S M, Pilgrim A J (1990) A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 30: 795-803
30. McEvoy J P, Hogarty G E, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archs Gen Psychiat 48: 739-745
31. MacKay A V P (1981) Assessment of antipsychotic drugs. Br J Clin Pharmac 11: 225-236
32. Mannion M F, Lynch G, King D J (1994) Precision of measures of saccadic eye movements and conventional psychomotor function tests. Hum Psychopharmac 9: 37-41
33. Miller A L, Maas J W, Contreras S, Seleshi E, True J E, Bowden C, Castiglioni J (1993) Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiat 34: 178-187
34. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiat 33: 227-235
35. Orme M, Harry J, Routledge P, Hobson S (1989) Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field. Br J Clin Pharmac 27: 125-133
36. Posner M I, Petersen S E (1990) The attention system of the human brain. Ann Rev Neurosci 13: 25-42
37. Royal College of Physicians (1986) Research on healthy volunteers: A report of the Royal College of Physicians. J R Coll Phys Lond 20: 243-257
38. Saario I (1976) Psychomotor skills during subacute treatment with thioridazine and bromazepam, and their combined effects with alcohol. Ann Clin Res 8: 117-123
39. Saletu B (1987) The use of pharmaco-EEG in drug profiling. In Hindmarch I, Stonier P D (eds), Human psychopharmacology, measures and methods, Vol. 1. John Wiley, Chichester, pp. 173-200
40. Saletu B, Küfferle B, Grünberger J, Anderer P (1986) Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 19: 434-437
41. Saletu B, Anderer P, Kinsperger K, Grünberger J (1987a) Topographic brain mapping of EEG in neuropsychopharmacology - II. Clinical applications (Pharmaco EEG imaging). Meth Find Exp Clin Pharmac 9: 385-408
42. Saletu B, Grünberger J, Linzmayer L, Anderer P (1987b) Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry 20: 12-27
43. Saletu B, Küfferle B, Anderer P, Grünberger J, Steinberger K (1990) EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur Neuropsychopharmac 1: 27-36
44. Saletu B, Barbanoj M J, Anderer P, Sieghart W, Grünberger J (1993) Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation. Meth Find Exp Clin Pharmac 15: 291-312
45. Saletu B, Küfferle B, Grünberger J, Földes P, Topitz A, Anderer P (1994) Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology 29: 125-135
46. Shallice T, Burgess P W, Frith C D (1991) Can the neuropsychological case-study approach be applied to schizophrenia? Psychol Med 21: 661-673
47. van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Archs Gen Psychiat 31: 67-72
48. van Putten T, Marder, S R (1986) Toward a more reliable diagnosis of akathisia. Archs Gen Psychiat 43: 1015-1016
49. Williams J H, Wellman N A, Geaney D P, Cowen P J, Feldon J, Rawlins J N P (1997) Latent inhibition is not reduced in drug-free patients with schizophrenia. Biol Psychiat, in press
50. Wittenborn J R (1977) Guidelines for clinical trials of psychotropic drugs. Pharmakopsychiatric Neuro-Psychopharmakologie, Georg Thieme Verlag, Stuttgart
51. World Health Organization (1985) Guidelines for the clinical investigation of neuroleptic drugs. European Drug Guideline Series 6. Regional Office for Europe, Copenhagen